This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Aguilar, D. Articles by Deswal, A. Search for Related Content PubMed Articles by Aguilar, D. Articles by Deswal, A. Related Collections Related Article

The Impact of Thiazolidinedione Use on Outcomes in Ambulatory Patients With Diabetes Mellitus and Heart Failure

David Aguilar, MD^_*,_*, Biykem Bozkurt, MD, FACC^_*,, Allison Pritchett, MD, FACC^_*, Nancy J. Petersen, PhD and Anita Deswal, MD, MPH, FACC^_*,,

^_* Winters Center for Heart Failure Research and Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas
Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
Houston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Hazard Ratios for HF Hospitalization or Death in Subgroups of Patients on TZDs Versus Patients Not Receiving Insulin Sensitizers Subgroup analyses showing hazard ratios of heart failure (HF) hospitalization or death in patients on thiazolidinediones (TZDs) versus patients not receiving insulin sensitizers. *Interaction p value = 0.03. GFR = glomerular filtration rate; LVEF = left ventricular ejection fraction.